As abnormal kidney function [22] as well as blood urea nitrogen (BUN) to serum albumin ratio [23] were found to predict adverse outcomes in COVID-19 patients, the present study aims to assess the levels of yet another novel and more complex composite marker, namely Lactate dehydrogenase/Albumin to-urea ratio in hospitalised COVID-19 patients, with and without fatal clinical complications post infection. The gene discussed is ALB; the disease is COVID-19.